Cellectis (ALCLS) Q1 2025 earnings summary

Executive summary

• Reported Q1 2025 financial results and provided business updates on clinical and research programs, including progress in Phase 1 studies for lasme-cel (UCART22) in r/r B-ALL and eti-cel (UCART20x22) in r/r NHL, with key data readouts expected in Q3 and late 2025.

• Ongoing R&D collaboration with AstraZeneca on three cell and gene therapy programs, contributing to revenue growth.

• Presented novel non-viral gene editing and base editing research at the 2025 ASGCT annual meeting.

Financial highlights

• Cash position of $246 million as of March 31, 2025, down from $264 million at December 31, 2024, providing runway into H2 2027.

• Q1 2025 revenues and other income totaled $12.0 million, up from $6.5 million in Q1 2024, mainly due to increased revenue from the AstraZeneca partnership.

• R&D expenses were $21.9 million, slightly down from $22.3 million year-over-year; SG&A expenses decreased to $4.7 million from $5.1 million.

• Net loss attributable to shareholders was $18.1 million (or $0.18 per share) in Q1 2025, compared to net income of $5.6 million (or $0.08 per share) in Q1 2024, mainly due to a one-off $21.3 million gain in Q1 2024.

• Adjusted net loss was $17.2 million (or $0.17 per share) in Q1 2025, versus adjusted net income of $6.5 million (or $0.09 per share) in Q1 2024.

Outlook and guidance

• Cash, cash equivalents, and fixed-term deposits expected to fund operations into H2 2027.

• Focus remains on advancing core clinical programs and AstraZeneca collaboration, with key clinical data readouts anticipated in Q3 and late 2025.